Coles began his career in pharmaceuticals, holding executive roles at
Merck & Co. (marketing
ACE inhibitors),
Bristol-Myers Squibb (senior vice president of strategy and policy, and marketing for neuroscience and infectious diseases), and
Vertex Pharmaceuticals (senior vice president of commercial operations). He was president and CEO of
Onyx Pharmaceuticals from 2008 to 2013, and chairman from 2012 to 2013, overseeing its $10.4 billion sale to
Amgen in 2013. In 2014, Coles co-founded
Yumanity Therapeutics with Susan Lindquist, serving as chairman and CEO until 2018, focusing on treatments for Alzheimer’s and Parkinson’s diseases. At
Cerevel Therapeutics, Coles served as CEO from 2019 to 2023, leading a $445 million public listing in 2020, and has been chairman since 2018. == Civic and professional affiliations ==